| Politician | Action | Description | Traded |
|---|---|---|---|
| Buy | VERTEX PHARMACEUTICALS INCOR | Jun 2, 2026 | |
| Buy | VERTEX PHARMACEUTICALS INC/C | Apr 30, 2026 | |
| Sell | VERTEX ANALYTICS, INC CMN | Apr 24, 2026 | |
| Buy | VERISK ANALYTICS, INC CMN | Apr 24, 2026 | |
| Buy | VERTEX ANALYTICS, INC CMN | Apr 20, 2026 | |
| Buy | VERTEX PHARMACEUTICALS INCOR | Apr 20, 2026 | |
| Sell | VERTEX ANALYTICS, INC CMN | Apr 2, 2026 | |
| Buy | VERISIGN ANALYTICS, INC CMN | Apr 2, 2026 | |
| Buy | Vertex Pharmaceuticals Incor | Mar 27, 2026 | |
| Sell | MGMT INTRACITECHNOLOGY INC | Feb 24, 2026 |
This page tracks congressional stock trading activity in Vertex Pharmaceuticals Incorporated (VRTX) in the Healthcare sector. Disclosed Capitol has indexed 134 disclosed congressional trades involving VRTX. Every trade is sourced from official STOCK Act financial disclosure filings — the same primary records the Senate and House are required to publish. The full trade list with politician names, transaction types, amount ranges, and disclosure dates is below, alongside cross-references to any related lobbying activity, federal contracts, and committee assignments.
As of August 2026 — Disclosed Capitol has tracked 134 disclosed congressional trades in Vertex Pharmaceuticals Incorporated (VRTX) — 67:36 sell-heavy ratio — led by Ro Khanna (D).
| Date | Politician | Party | Action | Amount |
|---|---|---|---|---|
| Jun 2, 2026 | Ro Khanna | D | Buy | $1,001 - $15,000 |
| Apr 30, 2026 | Ro Khanna | D | Buy | $1,001 - $15,000 |
| Apr 24, 2026 | Ro Khanna | D | Sell | $15,001 - $50,000 |
| Apr 24, 2026 | Ro Khanna | D | Buy | $1,001 - $15,000 |
| Apr 20, 2026 | Ro Khanna | D | Buy | $1,001 - $15,000 |
| Apr 20, 2026 | Ro Khanna | D | Buy | $1,001 - $15,000 |
| Apr 2, 2026 | Ro Khanna | D | Sell | $1,001 - $15,000 |
| Apr 2, 2026 | Ro Khanna | D | Buy | $1,001 - $15,000 |
| Mar 27, 2026 | Alan Armstrong | R | Buy | $1,001 - $15,000 |
| Feb 24, 2026 | Michael McCaul | R | Sell | $250,001 - $500,000 |
Across the 134 disclosed congressional trades in Vertex Pharmaceuticals Incorporated (VRTX), members of Congress have reported 36 buys and 67 sells. The average 30-day alpha vs. the S&P 500 is 0.21%.
As of October 2025, Vertex Pharmaceuticals Incorporated has 88 federal contract award records on file from USAspending.gov — most recently -$69K from the Department of Defense on 2025-10-16.
| Award date | Agency | Amount |
|---|---|---|
| 2025-10-16 | Department of Defense · Defense Logistics Agency | -$69K |
| 2025-10-03 | Department of Defense · Defense Logistics Agency | $69K |
| 2025-09-15 | Department of Defense · Department of the Air Force | $660K |
| 2025-05-08 | Department of Defense · Defense Logistics Agency | -$167K |
| 2025-04-18 | Department of Defense · Defense Logistics Agency | -$180K |
| 2025-04-11 | Department of Defense · Defense Logistics Agency | -$84K |
| 2025-04-02 | Department of Defense · Defense Logistics Agency | $117K |
| 2025-03-26 | Department of Defense · Defense Logistics Agency | $84K |
| 2025-02-13 | Department of Defense · Defense Logistics Agency | $55K |
| 2025-02-06 | Department of Defense · Defense Logistics Agency | $167K |
Negative amounts are contract de-obligations. Browse and filter every award on the government contracts page.
For fiscal year 2025, Vertex Pharmaceuticals Incorporated reported revenue of $12.00B and net income of $3.95B, per SEC filings.
Most recent reported quarter: Q2 FY2026 — revenue $3.33B, net income $1.10B.
Figures come from SEC financial statement filings. The full annual and quarterly statement history is in the Financials tab above.